Bayer's anetumab ravtansine misses in Phase II for mesothelioma

Bayer AG (Xetra:BAYN) reported data from a Phase II trial in 248 patients with malignant pleural mesothelioma (MPM) showing that second-line treatment with IV anetumab ravtansine (BAY 94-9343) every 3 weeks missed the primary endpoint of improving progression-free survival (PFS) vs. vinorelbine. The open-label, international trial enrolled patients with advanced or metastatic mesothelin-positive MPM whose disease progressed after treatment with first-line platinum/Alimta pemetrexed-based chemotherapy...